Metraipolis › archive › dc_379c8608fa50
Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation — Europe PMC PMID:42812201
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42812201
- DOI
- 10.3389/fphar.2026.1926844
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T13:11:48.926Z
- SHA-256 of the archived text
7880b749a3722d50548fcbfa770a1c22718a795ef55e2ebee6b41ca922d1be60- Stable URL of this page
https://metraipolis.com/documento/dc_379c8608fa50
How to cite
Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation — Europe PMC PMID:42812201 — Europe PMC (en), https://europepmc.org/article/MED/42812201 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_379c8608fa50 (Metraipolis archive dc_379c8608fa50, sha256 7880b749a3722d50548fcbfa770a1c22718a795ef55e2ebee6b41ca922d1be60)
BibTeX
@misc{dc379c8608fa50,
title = {Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation — Europe PMC PMID:42812201},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42812201},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_379c8608fa50; sha256 7880b749a3722d50548fcbfa770a1c22718a795ef55e2ebee6b41ca922d1be60},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42812201. Agents can read the archived copy with the MCP tool read_document.